Immune Checkpoint Inhibitors
- Immune Checkpoint Inhibitors
- Accession Number
Immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the “off” signal from being sent, allowing the T cells to kill cancer cells.
Drug Drug Description Ipilimumab A human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. Nivolumab A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. Pembrolizumab A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. Cemiplimab A programmed death receptor-1 blocking antibody used to treat metastatic cutaneous squamous cell carcinoma. Spartalizumab Spartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma). Camrelizumab Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy). Sintilimab Not Annotated Tislelizumab Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors). Toripalimab Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC). Dostarlimab An anti-PD-1 monoclonal antibody used in the treatment of mismatch repair deficient endometrial cancers. Retifanlimab Not Annotated AMP-224 Not Annotated MEDI0680 Not Annotated Atezolizumab A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy. Avelumab A monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma. Durvalumab An antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer. Envafolimab Not Annotated Cosibelimab Not Annotated AUNP-12 Not Annotated CA-170 CA-170 is a selective, small molecule inhibitor of PD-L1. anti-OX40 antibody BMS 986178 A macrocyclic peptide (BMS-986189) with activity in binding and functional assays comparable to a PD-L1 antibody. Tremelimumab Tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part...
- Drugs & Drug Targets